Screener
Eikon Therapeutics, Inc. EIKN Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Eikon Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: Eikon Therapeutics, Inc.’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 4:13 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-216791
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Research and development | $70,047 | $56,587 |
| General and administrative | 17,290 | 14,796 |
| Total operating expenses | 87,337 | 71,383 |
| Loss from operations | (87,337) | (71,383) |
| Interest income (expense), net | 4,380 | 3,160 |
| Other income (expense), net | (1) | (20) |
| Net loss and comprehensive loss | (82,958) | (68,243) |
| Impact of preferred stock extinguishments and modifications | — | (6,300) |
Item 1. Condensed Financial Statements (Unaudited).
FAQ
- What is Eikon Therapeutics, Inc.'s operating income?
- Eikon Therapeutics, Inc. (EIKN) reported operating income of -$87.34M in Q1 2026.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.
Ask your AI about Eikon Therapeutics, Inc.'s operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude